To date, JCV antibody testing for PML risk reduction has been validated only with natalizumab because the observed incidence of PML is sufficiently high enough to enable estimated risk stratification in patients with multiple sclerosis (Lee et al. 2013). This evidence concerns the gene PML and progressive multifocal leukoencephalopathy.